Atopic Dermatitis Therapeutics Market Size in 7MM was ~USD 17 Billion in 2023 is expected to grow by 2034 | DelveInsight

Atopic Dermatitis Drugs Market

Atopic Dermatitis Therapeutics Market

NV, UNITED STATES, December 18, 2024 /EINPresswire.com/ -- DelveInsight’s “Atopic Dermatitis Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of the Atopic Dermatitis, historical and forecasted epidemiology as well as the Atopic Dermatitis market trends in the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, Japan.

Discover Key Insights into the Atopic Dermatitis Market with DelveInsight's In-Depth Report @ Atopic Dermatitis Market Size

Key Takeaways from the Atopic Dermatitis Market Report
• In December 2024:- Incyte Corporation- This study is being conducted to establish the efficacy of ruxolitinib cream in participants with moderate AD who had an inadequate response to, or are intolerant to, or contraindicated to topical corticosteroid (TCS)s and topical calcineurin inhibitor (TCI)s.
• In December 2024:- Amgen- A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD).
• In December 2024:- Eli Lilly and Company- This study will also include an Addendum to extend the study treatment period by an additional 32 weeks and to add a treatment arm testing dosing every 8 weeks. This Addendum will apply to existing study participants in selected countries.
• ~40% of the Atopic Dermatitis prevalent population is ≤ 18 years of age; ~60%of this population has an early onset i.e. at the age of 0-2 years.
• The United States accounted for the highest number of Atopic dermatitis prevalent cases in the 7MM.
• Diagnosis of atopic dermatitis remains of key importance. ~25% remain either undiagnosed or misdiagnosed. Also, a significant delay in diagnosis had been associated with the disease.
• The leading Atopic Dermatitis Companies such as Sanofi, Regeneron Pharmaceuticals, Pfizer, Japan Tobacco and Torii Pharmaceutical, Eli Lilly and Company, AbbVie, LEO Pharma, Incyte Corporation, Arena Pharmaceuticals, Oneness Biotech, Galderma, DS Biopharma, Janssen, Kymab, Arcutis Biotherapeutics, Qurient, Cara Therapeutics, Vanda Pharmaceuticals, and others.
• Promising Atopic Dermatitis Therapies such as Dupilumab, Apremilast, EDP1815, BMS-986166, Branebrutinib, Tofacitinib ointment 20mg/g, MEDI3506, Lebrikizumab, and others.

Discover which therapies are expected to grab the Atopic Dermatitis Market Share @ Atopic Dermatitis Market Outlook

Atopic Dermatitis Epidemiology Segmentation in the 7MM
• Total Prevalent Cases of Atopic Dermatitis in the 7MM
• Total Prevalent Cases of Atopic Dermatitis by Age in the 7MM
• Total Diagnosed Cases of Atopic Dermatitis in the 7MM
• Total Diagnosed Cases of Atopic Dermatitis by Severity in the 7MM
• Total Diagnosed Cases of Atopic Dermatitis by Gender in the 7MM
• Total Treated Cases of Atopic Dermatitis in the 7MM

Download the report to understand which factors are driving Atopic Dermatitis Epidemiology trends @ Atopic Dermatitis Prevalence

Atopic Dermatitis Marketed Therapies

• RINVOQ (upadacitinib): AbbVie
Upadacitinib (ABT-494) – discovered and developed by AbbVie scientists and marketed as RINVOQ – is a selective and reversible JAK inhibitor. JAKs are intracellular enzymes that transmit signals arising from cytokine or growth factor-receptor interactions on the cellular membrane to influence cellular processes of hematopoiesis and immune cell function. Within the signaling pathway, JAKs phosphorylate and activate signal transducers and activators of transcription (STATs), which modulate intracellular activity, including gene expression. Upadacitinib modulates the signaling pathway at the point of JAKs, preventing the phosphorylation and activation of STATs.

• DUPIXENT (dupilumab): Sanofi/Regeneron Pharmaceuticals
DUPIXENT (dupilumab) is an interleukin-4 (IL-4) receptor alpha antagonist. It is a human monoclonal antibody of the immunoglobulin G4 subclass that inhibits IL-4 and interleukin-13 (IL-13) signaling by specifically binding to the IL-4 receptor alpha subunit, which the IL-4 and IL-13 receptor complexes share. Dupilumab inhibits IL-4 signaling via the type 1 receptor and both IL-4 and IL-13 signaling via the type 2 receptor.

Atopic Dermatitis Emerging Therapies
• Rocatinlimab (KHK4083/AMG 451): Amgen/Kyowa Kirin
Rocatinlimab (KHK4083/AMG 451) is an anti-OX40 human monoclonal antibody that inhibits and reduces the number of OX40-expressing pathogenic T cells responsible for driving systemic and local inflammatory responses. It has been reported that effector T cells expressing OX40 are present in the lesions of patients with atopic dermatitis and are critical in the disease pathophysiology. The initial antibody was discovered in collaboration between Kyowa Kirin US Research and La Jolla Institute for Immunology.

• VTAMA (tapinarof; JTE-061): Dermavant Sciences/Japan Tobacco Pharmaceutical/Torii Pharmaceutical
Tapinarof is a novel aryl hydrocarbon receptor agonist in development as a once-daily, steroid-free, and cosmetically elegant topical cream. Dermavant is developing it for the treatment of psoriasis and atopic dermatitis. Over 1,400 subjects have participated in 12 clinical trials for tapinarof. In the US, VTAMA cream is approved for the topical treatment of plaque psoriasis in adults.

To know more about Atopic Dermatitis treatment guidelines, visit @ Atopic Dermatitis Treatment Market Landscape- https://www.delveinsight.com/sample-request/atopic-dermatitis-market?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=ypr

Atopic Dermatitis Companies
Sanofi, Regeneron Pharmaceuticals, Pfizer, Japan Tobacco and Torii Pharmaceutical, Eli Lilly and Company, AbbVie, LEO Pharma, Incyte Corporation, Arena Pharmaceuticals, Oneness Biotech, Galderma, DS Biopharma, Janssen, Kymab, Arcutis Biotherapeutics, Qurient, Cara Therapeutics, Vanda Pharmaceuticals, and others.

Atopic Dermatitis Market Outlook
Several effective Atopic Dermatitis treatments have become available in recent years for adult and adolescent patients with Atopic Dermatitis, and more are in development. The current Atopic Dermatitis market uses several off-label therapies apart from pharmacological systemic treatment. Localized atopic itch is frequently treated with topical or intralesional therapeutic agents. Topical corticosteroids have been used for atopic dermatitis for decades. Pimecrolimus and tacrolimus, topical calcineurin inhibitors, are used as steroid-sparing agents for patients with atopic dermatitis. Phosphodiesterase-4 (PDE-4) inhibitors are an alternative option for the topical treatment of pruritis in atopic dermatitis. Oral antihistamines are commonly used for atopic itch. Additionally, phototherapy is efficacious in targeting atopic itch.

Learn more about the FDA-approved drugs for Atopic Dermatitis @ Drugs for Atopic Dermatitis Treatment- https://www.delveinsight.com/sample-request/atopic-dermatitis-market?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Atopic Dermatitis Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Atopic Dermatitis Companies- Sanofi, Regeneron Pharmaceuticals, Pfizer, Japan Tobacco and Torii Pharmaceutical, Eli Lilly and Company, AbbVie, LEO Pharma, Incyte Corporation, Arena Pharmaceuticals, Oneness Biotech, Galderma, DS Biopharma, Janssen, Kymab, Arcutis Biotherapeutics, Qurient, Cara Therapeutics, Vanda Pharmaceuticals, and others.
• Atopic Dermatitis Therapies- Dupilumab, Apremilast, EDP1815, BMS-986166, Branebrutinib, Tofacitinib ointment 20mg/g, MEDI3506, Lebrikizumab, and others.
• Atopic Dermatitis Market Dynamics: Atopic Dermatitis Market Drivers and Barriers
• Atopic Dermatitis Market Access and Reimbursement, Unmet Needs and Future Perspectives

Table of Content
1. Key Insights
2. Report Introduction
3. Atopic Dermatitis (AD) Market Overview at a Glance
4. Epidemiology and Market Methodology
5. Executive Summary
6. Disease Background and Overview
7. Epidemiology and Patient Population
8. Patient Journey
9. Key Endpoints in Atopic Dermatitis Clinical Trials
10. Marketed Therapies
11. Emerging Therapies
12. Atopic Dermatitis (Atopic Dermatitis): The 7MM Analysis
13. Market Access and Reimbursement
14. KOL Views
15. SWOT Analysis
16. Unmet Needs
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer

List of the Top Selling Market Research Reports in 2024

Yash Bhardwaj
DelveInsight
+91 9650213330
email us here

Distribution channels: Healthcare & Pharmaceuticals Industry

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Submit your press release